ft 30 dec 92 glaxo win us approv migrain drug glaxo uk largest pharmaceut compani yesterday secur approv us sale one biggest sell drug 1990 sumatriptan migrain treatment food drug administr fda control drug sold us approv inject version tablet like approv late 1993 approv came quickli observ fear drug treat life threaten condit thought low fda list prioriti approv help glaxo share rise 27p 774p trade heavi london new york share also quot sumatriptan avail prescript us late march name imitrex glaxo said brand name market imigran 33 countri alreadi approv drug spite critic especi franc price glaxo charg high price pound 40 two dose sumatriptan much effect rival treatment patient glaxo last financi year june 1992 sale sumatriptan reach pound 43m analyst believ sale current year doubl within five year drug could blockbust usual defin industri sale dollar 1bn pound 600m year half us us approv import glaxo world second largest drug compani best sell ulcer treatment zantac lose market share new rival losec made swedish compani astra howev sumatriptan unlik replac zantac compani main sourc profit zantac sale still grow sumatriptan one albeit import new gener glaxo drug other serev asthma treatment zofran reduc nausea chemotherapi patient flixonas anti inflammatori design help peopl allergi four could account 25 per cent glaxo sale within five year said mr jonathan gell analyst new york stockbrok wertheim schroder london stock exchang page 26